Sequence determinants of a specific inactive protein kinase conformation.

Only a small percentage of protein kinases have been shown to adopt a distinct inactive ATP-binding site conformation, called the Asp-Phe-Gly-out (DFG-out) conformation. Given the high degree of homology within this enzyme family, we sought to understand the basis of this disparity on a sequence level. We identified two residue positions that sensitize mitogen-activated protein kinases (MAPKs) to inhibitors that stabilize the DFG-out inactive conformation. After characterizing the structure and dynamics of an inhibitor-sensitive MAPK mutant, we demonstrated the generality of this strategy by sensitizing a kinase (apoptosis signal-regulating kinase 1) not in the MAPK family to several DFG-out stabilizing ligands, using the same residue positions. The use of specific inactive conformations may aid the study of noncatalytic roles of protein kinases, such as binding partner interactions and scaffolding effects.

[1]  S. Knapp,et al.  Structural Comparison of Human Mammalian Ste20-Like Kinases , 2010, PloS one.

[2]  D. Boehr,et al.  The Dynamic Energy Landscape of Dihydrofolate Reductase Catalysis , 2006, Science.

[3]  Wei-Sheng Huang,et al.  Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. , 2010, Journal of medicinal chemistry.

[4]  Paul Bamborough,et al.  Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. , 2008, Bioorganic & medicinal chemistry letters.

[5]  Harald Schwalbe,et al.  NMR characterization of kinase p38 dynamics in free and ligand-bound forms. , 2006, Angewandte Chemie.

[6]  John Kuriyan,et al.  Activation of tyrosine kinases by mutation of the gatekeeper threonine , 2008, Nature Structural &Molecular Biology.

[7]  J. Woska,et al.  Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. , 2009, Biochemical pharmacology.

[8]  Dustin J Maly,et al.  Active site profiling reveals coupling between domains in SRC-family kinases , 2012, Nature chemical biology.

[9]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[10]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[11]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[12]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[13]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[14]  R. Nussinov,et al.  Folding funnels, binding funnels, and protein function , 1999, Protein science : a publication of the Protein Society.

[15]  P. Caron,et al.  Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. , 1998, Structure.

[16]  Dustin J Maly,et al.  Determination of the kinetics and thermodynamics of ligand binding to a specific inactive conformation in protein kinases. , 2012, Methods in molecular biology.

[17]  Harald Schwalbe,et al.  NMR Backbone Assignment of a Protein Kinase Catalytic Domain by a Combination of Several Approaches: Application to the Catalytic Subunit of cAMP‐Dependent Protein Kinase , 2004, Chembiochem : a European journal of chemical biology.

[18]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[19]  K. Wilson,et al.  Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[20]  J. Cortes,et al.  Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia , 2008, Clinical Cancer Research.

[21]  J. Kuriyan,et al.  c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. , 2007, Structure.

[22]  T. Hunter,et al.  Evolution of protein kinase signaling from yeast to man. , 2002, Trends in biochemical sciences.

[23]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[24]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[25]  Yi Liu,et al.  Generation of Monospecific Nanomolar Tyrosine Kinase Inhibitors via a Chemical Genetic Approach , 1999 .

[26]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[27]  Elizabeth J. Goldsmith,et al.  Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution , 1994, Nature.

[28]  J. S. Johnson,et al.  1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[29]  K. Wilson,et al.  A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase , 1998, Protein science : a publication of the Protein Society.

[30]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[31]  P. Gallant,et al.  Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[32]  R. Dror,et al.  A conserved protonation-dependent switch controls drug binding in the Abl kinase , 2009, Proceedings of the National Academy of Sciences.

[33]  S. Hubbard,et al.  Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.

[34]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[35]  Dustin J Maly,et al.  Affinity-based probes based on type II kinase inhibitors. , 2012, Journal of the American Chemical Society.

[36]  E. Casale,et al.  Through the "gatekeeper door": exploiting the active kinase conformation. , 2010, Journal of medicinal chemistry.

[37]  Xin Huang,et al.  Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. , 2006, Journal of medicinal chemistry.

[38]  Alexandre G. de Brevern,et al.  A Novel Evaluation of Residue and Protein Volumes by Means of Laguerre Tessellation , 2010, J. Chem. Inf. Model..

[39]  John Kuriyan,et al.  Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. , 2009, Cancer research.

[40]  Zhi-Xin Wang,et al.  Enzymatic Activity and Substrate Specificity of Mitogen-activated Protein Kinase p38α in Different Phosphorylation States* , 2008, Journal of Biological Chemistry.

[41]  Bo Zhou,et al.  The Activity of the Extracellular Signal-regulated Kinase 2 Is Regulated by Differential Phosphorylation in the Activation Loop* , 2002, The Journal of Biological Chemistry.

[42]  Lynn F. Ten Eyck,et al.  A helix scaffold for the assembly of active protein kinases , 2008, Proceedings of the National Academy of Sciences.

[43]  Adrian H Elcock,et al.  Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase. , 2006, Journal of molecular biology.

[44]  Angela Greco,et al.  A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.

[45]  Elizabeth J. Goldsmith,et al.  Activation Mechanism of the MAP Kinase ERK2 by Dual Phosphorylation , 1997, Cell.

[46]  Dustin J Maly,et al.  A hexylchloride-based catch-and-release system for chemical proteomic applications. , 2013, ACS chemical biology.

[47]  D. Koshland.  Application of a Theory of Enzyme Specificity to Protein Synthesis. , 1958, Proceedings of the National Academy of Sciences of the United States of America.

[48]  K. Resing,et al.  The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity , 2006, Proceedings of the National Academy of Sciences.

[49]  Susan S. Taylor,et al.  Defining the Conserved Internal Architecture of a Protein Kinase , 2010, Biochimica et biophysica acta.

[50]  J. Kuriyan,et al.  Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. , 2011, Molecular cell.

[51]  P. Crespo,et al.  Working Without Kinase Activity: Phosphotransfer-Independent Functions of Extracellular Signal–Regulated Kinases , 2011, Science Signaling.

[52]  Susan S. Taylor,et al.  Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism , 2006, Proceedings of the National Academy of Sciences.

[53]  E. Goldsmith,et al.  The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Amanda M. Brock,et al.  Affinity reagents that target a specific inactive form of protein kinases. , 2010, Chemistry & biology.

[55]  Jon Read,et al.  Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase. , 2005, Biochemistry.

[56]  G. Rubin,et al.  KSR modulates signal propagation within the MAPK cascade. , 1996, Genes & development.

[57]  Chao Zhang,et al.  A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases , 2005, Nature Methods.

[58]  Roger J. Davis,et al.  Differential activation of p38MAPK isoforms by MKK6 and MKK3. , 2010, Cellular signalling.

[59]  E. Schönbrunn,et al.  A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. , 2012, ACS chemical biology.

[60]  F. Lu,et al.  The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.

[61]  Jürg Zimmermann,et al.  Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .